A Young Hematologist’s Take on ICML 2025

At the ICML 2025, Dr. Bruce Cheson and Dr. Emanuele Zucca highlighted the evolution of lymphoma treatments over the decades, celebrating milestones like the introduction of bendamustine and the innovative R-squared approach. The conference explored advancements such as molecular classifiers DLBclass and LymphGen, enhancing disease prognosis and treatment strategies. Key findings from recent trials showed significant improvements in overall survival and progression-free rates when utilizing new therapies, indicating a transformative shift in lymphoma management.